{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:17Z","timestamp":1792887797982,"version":"4.5.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2009,5,14]],"date-time":"2009-05-14T00:00:00Z","timestamp":1242259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0005268","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T21:26:18Z","timestamp":1242249978000},"page":"e5268","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":154,"title":["Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy"],"prefix":"10.1371","volume":"4","author":[{"given":"Kathryn J.","family":"Swoboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"LaSalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Sorenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Acsadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Kissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Krosschell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"D'Anjou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Schroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakri","family":"Elsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2009,5,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s001090050059","article-title":"Spinal muscular atrophies: recent insights and impact on molecular diagnosis.","volume":"74","author":"C Brahe","year":"1996","journal-title":"J Mol Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/adc.45.239.33","article-title":"The genetic component in child mortality.","volume":"45","author":"DF Roberts","year":"1970","journal-title":"Arch Dis Child"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.","volume":"15","author":"J Pearn","year":"1978","journal-title":"J Med Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jmg.26.12.761","article-title":"A hungarian study on Werdnig-Hoffmann disease.","volume":"26","author":"A Czeizel","year":"1989","journal-title":"J Med Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2013a world survey.","volume":"1","author":"AE Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0960-8966(92)90006-R","article-title":"Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy.","volume":"2","author":"L Merlini","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and Characterization of a Spinal Muscular Atrophy-determining Gene.","volume":"80","author":"S Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref8","first-page":"5543","article-title":"The Survival of Motor Neurons Protein Determines the Capacity for snRNP Assembly: Biochemical Deficiency in Spinal Muscular Atrophy.","volume":"25(13)","author":"L Wan","year":"1995","journal-title":"Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.","volume":"96","author":"CL Lorson","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref10","first-page":"358","article-title":"Am J Hum Genet.","volume":"70(2)","author":"M Feldkotter","year":"2002"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular Analysis of Spinal Muscular Atrophy and Modification of the Phenotype by SMN2.","volume":"4","author":"MD Mailman","year":"2002","journal-title":"Genet Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.","volume":"57","author":"KJ Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number.","volume":"119","author":"B Wirth","year":"2006","journal-title":"Hum Genet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajmg.a.30251","article-title":"Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2.","volume":"130","author":"TW Prior","year":"2004","journal-title":"Am J Med Genet A"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy.","volume":"16","author":"S Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate.","volume":"98","author":"JG Chang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.","volume":"12","author":"L Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells.","volume":"54","author":"CJ Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy.","volume":"12","author":"C Andreassi","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.","volume":"58","author":"SM Grzeschik","year":"2005","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In Vivo Activation of SMN in Spinal Muscular Atrophy Carriers and Patients Treated with Valproate.","volume":"59","author":"L Brichta","year":"2006","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients.","volume":"13","author":"C Brahe","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression.","volume":"14","author":"LE Kernochan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1523\/JNEUROSCI.0096-06.2006","article-title":"Endogenous \u03b1-Synuclein is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity.","volume":"26(28)","author":"Y Leng","year":"2006","journal-title":"J Neurosci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1747-0285.2006.00369.x","article-title":"Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein.","volume":"67","author":"J van Bergeijk","year":"2006","journal-title":"Chem Biol Drug Des"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1111\/j.1460-9568.2004.03765.x","article-title":"Benefit of valproic acid in suppressing disease progression of ALS model mice.","volume":"20","author":"F Sugai","year":"2004","journal-title":"Eur J Neurosci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2005.09.013","article-title":"Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.","volume":"22","author":"S Petri","year":"2006","journal-title":"Neurobiol Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.nbd.2006.07.004","article-title":"Establishing a standardized therapeutic testing protocol for spinal muscular atrophy.","volume":"24","author":"LK Tsai","year":"2006","journal-title":"Neurobiol Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","article-title":"Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice.","volume":"86","author":"LK Tsai","year":"2008","journal-title":"J Mol Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscular atrophy.","volume":"67","author":"CC Weihl","year":"2006","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy.","volume":"14","author":"LK Tsai","year":"2007","journal-title":"Eur J Neurol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.","volume":"7","author":"M Main","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nmd.2006.03.015","article-title":"A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.","volume":"16","author":"KJ Krosschell","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2005.11.010","article-title":"Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a Multicentric Study.","volume":"16","author":"E Mercuri","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy.","volume":"25","author":"MB Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1212\/01.wnl.0000252934.70676.ab","article-title":"Pre-clinical validation of a multiplex real-time RT-PCR assay to quantify SMN transcripts in whole blood from SMA patients.","volume":"68","author":"LR Simard","year":"2007","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/01.wnl.0000201929.56928.13","article-title":"SMN mRNA and protein levels in peripheral blood.","volume":"66","author":"CJ Sumner","year":"2006","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3476(94)70218-7","article-title":"Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid.","volume":"125","author":"B Melegh","year":"1994","journal-title":"J Pediatr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0887-8994(94)00100-G","article-title":"Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)?","volume":"12","author":"I Tein","year":"1995","journal-title":"Pediatr Neurol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/1531-8249(199903)45:3<337::AID-ANA9>3.0.CO;2-U","article-title":"Abnormal fatty acid metabolism in childhood spinal muscular atrophy.","volume":"45","author":"TO Crawford","year":"1999","journal-title":"Ann Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(84)92209-8","article-title":"Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.","volume":"1(8378)","author":"DL Coulter","year":"1984","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/jpem-2006-190411","article-title":"Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3.","volume":"19","author":"S Kumandas","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2003.11.011","article-title":"The effect of valproate on bone mineral density in adult epileptic patients.","volume":"50","author":"A Boluk","year":"2004","journal-title":"Pharmacol Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2004.03.021","article-title":"Effect of carbamazepine and valproate on bone mineral density.","volume":"31","author":"C Ecevit","year":"2004","journal-title":"Pediatr Neurol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/01.bpo.0000235228.45539.c7","article-title":"Fractures in children with cerebral palsy.","volume":"26","author":"AI Leet","year":"2006","journal-title":"J Pediatr Orthop"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0005268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T09:40:41Z","timestamp":1710322841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0005268"}},"subtitle":[],"editor":[{"given":"Brian D.","family":"McCabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,5,14]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0005268","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,14]]}}}